Eli Lilly And Co (NYSE:LLY) Stock Rating Reaffirmed by Cantor Fitzgerald
Eli Lilly And Co (NYSE:LLY)‘s stock had its “buy” rating restated by Cantor Fitzgerald in a report released on Monday, TipRanks reports. They presently have a $143.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 22.49% from the company’s previous close.
LLY has been the subject of several other research reports. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Bank of America started coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Finally, UBS Group cut their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Eli Lilly And Co currently has an average rating of “Buy” and a consensus price target of $130.03.
Shares of Eli Lilly And Co stock traded down $0.61 on Monday, reaching $116.74. The company’s stock had a trading volume of 2,170,655 shares, compared to its average volume of 7,378,321. The company has a market capitalization of $112.61 billion, a price-to-earnings ratio of 21.03, a P/E/G ratio of 1.91 and a beta of 0.16. The firm’s fifty day simple moving average is $112.16 and its two-hundred day simple moving average is $112.43. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $132.13. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09.
In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 19,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the completion of the sale, the senior vice president now owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Stephen F. Fry sold 9,452 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $115.00, for a total value of $1,086,980.00. Following the sale, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The disclosure for this sale can be found here. In the last three months, insiders have acquired 8,405 shares of company stock valued at $909,004 and have sold 891,606 shares valued at $102,840,255. Insiders own 0.11% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Westside Investment Management Inc. purchased a new position in shares of Eli Lilly And Co in the second quarter valued at about $77,000. Brookstone Capital Management lifted its position in shares of Eli Lilly And Co by 6.4% in the second quarter. Brookstone Capital Management now owns 10,936 shares of the company’s stock valued at $1,212,000 after acquiring an additional 658 shares in the last quarter. Nelson Roberts Investment Advisors LLC lifted its position in shares of Eli Lilly And Co by 88.9% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 850 shares of the company’s stock valued at $94,000 after acquiring an additional 400 shares in the last quarter. Squar Milner Financial Services LLC lifted its position in shares of Eli Lilly And Co by 180.4% in the second quarter. Squar Milner Financial Services LLC now owns 2,456 shares of the company’s stock valued at $272,000 after acquiring an additional 1,580 shares in the last quarter. Finally, Royal Bank of Scotland Group PLC lifted its position in shares of Eli Lilly And Co by 27.1% in the second quarter. Royal Bank of Scotland Group PLC now owns 6,686 shares of the company’s stock valued at $741,000 after acquiring an additional 1,425 shares in the last quarter. 76.51% of the stock is owned by institutional investors and hedge funds.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Insider Trading – What You Need to Know
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.